A phase II study of cadonilimab plus FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)

Lin, R; Zhao, S; Su, L; Hong, Y; Luo, J; Wei, Y; Zhao, S

ANNALS OF ONCOLOGY, 2023; 34 (): S1519

Abstract

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索